BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+19.15%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.8B
AUM Growth
+$2.8B
(+14%)
Cap. Flow
-$238M
Cap. Flow
% of AUM
-8.49%
Top 10 Holdings %
Top 10 Hldgs %
76.91%
Holding
52
New
1
Increased
5
Reduced
8
Closed
8
Top Buys
| 1 |
Protagonist Therapeutics
PTGX
|
$35.2M |
| 2 |
Immunocore
IMCR
|
$32.1M |
| 3 |
Kymera Therapeutics
KYMR
|
$14.9M |
| 4 |
Verastem
VSTM
|
$5.41M |
| 5 |
TScan Therapeutics
TCRX
|
$488K |
Top Sells
| 1 |
CBIO
Crescent Biopharma, Inc. Common Stock
CBIO
|
$132M |
| 2 |
RAPT Therapeutics
RAPT
|
$64.7M |
| 3 |
Galapagos
GLPG
|
$36.5M |
| 4 |
VERV
Verve Therapeutics
VERV
|
$31.6M |
| 5 |
iTeos Therapeutics
ITOS
|
$18.4M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $932M | 33.31% | 19,751,284 | – | – |
|
|
2
Kymera Therapeutics
KYMR
$2.95B
| $240M | 8.58% | 5,502,710 +340,909 | +7% | +$14.9M |
|
3
Revolution Medicines
RVMD
$7.1B
| $183M | 6.55% | 4,982,384 | – | – |
|
|
4
Protagonist Therapeutics
PTGX
$3.67B
| $177M | 6.34% | 3,211,041 +636,026 | +25% | +$35.2M |
|
5
Axsome Therapeutics
AXSM
$6.05B
| $176M | 6.3% | 1,690,221 | – | – |
|
6
Mirum Pharmaceuticals
MIRM
$3.71B
| $141M | 5.02% | 2,761,333 -35,180 | -1% | -$1.79M |
|
7
GH Research
GHRS
$837M
| $108M | 3.84% | 8,827,712 | – | – |
|
8
Ionis Pharmaceuticals
IONS
$6.79B
| $75.6M | 2.7% | 1,913,385 | – | – |
|
9
Xoma
XOMA
$392M
| $65.3M | 2.33% | 2,590,303 -392,723 | -13% | -$9.9M |
|
10
Zymeworks
ZYME
$1.12B
| $54.1M | 1.93% | 4,308,935 | – | – |
|
|
SEPN
11
Septerna, Inc. Common Stock
SEPN
$539M
| $46.5M | 1.66% | 4,396,124 | – | – |
|
12
Celcuity
CELC
$2.17B
| $46.3M | 1.65% | 3,466,000 | – | – |
|
13
Kura Oncology
KURA
$686M
| $44.7M | 1.6% | 7,754,129 | – | – |
|
14
Cullinan Oncology
CGEM
$445M
| $43.3M | 1.55% | 5,750,683 | – | – |
|
15
AC Immune
ACIU
$205M
| $40.2M | 1.44% | 19,822,436 | – | – |
|
16
Cidara Therapeutics
CDTX
$1.66B
| $38.3M | 1.37% | 786,392 -138,250 | -15% | -$6.73M |
|
17
Tyra Biosciences
TYRA
$675M
| $37.7M | 1.35% | 3,944,194 | – | – |
|
18
Structure Therapeutics
GPCR
$1.11B
| $36.7M | 1.31% | 1,771,417 | – | – |
|
|
19
Immunocore
IMCR
$1.62B
| $32.1M | 1.15% | +1,024,288 | New | +$32.1M |
|
20
Monte Rosa Therapeutics
GLUE
$296M
| $25.5M | 0.91% | 5,660,132 | – | – |
|
21
Foghorn Therapeutics
FHTX
$286M
| $24.9M | 0.89% | 5,302,000 | – | – |
|
22
Olema Pharmaceuticals
OLMA
$375M
| $22.6M | 0.81% | 5,295,893 | – | – |
|
|
CBIO
23
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $22.4M | 0.8% | 1,387,863 -8,156,399 | -85% | -$132M |
|
24
Xencor
XNCR
$580M
| $21.5M | 0.77% | 2,740,141 | – | – |
|
25
4D Molecular Therapeutics
FDMT
$288M
| $17.2M | 0.61% | 4,629,289 +68,000 | +1% | +$252K |
|